Abstract

Background

In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib.

Methods

We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety.

Results

Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib.

Conclusions

Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.

Details

Title
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
Author
Meza, Luis 1   VIAFID ORCID Logo  ; McDermott, David F 2 ; Escudier, Bernard 3 ; Hutson, Thomas E 4 ; Porta, Camillo 5 ; Verzoni, Elena 6 ; Atkins, Michael B 7 ; Kasturi, Vijay 8 ; Pal, Sumanta K 1 ; Rini, Brian 9 

1  Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA , USA 
2  Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center , Boston, MA , USA 
3  Department of Medical Oncology, Gustave Roussy , Villejuif , France 
4  Department of Hematology and Medical Oncology, Texas A&M University College of Medicine , Bryan, TX , USA 
5  Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro and Policlinico Consorziale di Bari , Bari , Italy 
6  Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori , Milan , Italy 
7  Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center , Washington, DC , USA 
8  Clinical Development and Medical Affairs, Aveo Oncology , Boston, MA , USA 
9  Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center , Nashville, TN , USA 
Pages
e167-e170
Publication year
2023
Publication date
Mar 2023
Publisher
Oxford University Press
ISSN
10837159
e-ISSN
1549490X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1093/oncolo/oyac255
ProQuest document ID
3190866507
Copyright
© The Author(s) 2022. Published by Oxford University Press. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.